Home/Pipeline/FT013

FT013

Diabetic nephropathy

PreclinicalActive

Key Facts

Indication

Diabetic nephropathy

Phase

Preclinical

Status

Active

Company

Certa Therapeutics

About Certa Therapeutics

Australian precision‑medicine biotech targeting fibrosis through GPR68 inhibition.

View full company profile

Therapeutic Areas

Fibrosis Nephrology